<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727399</url>
  </required_header>
  <id_info>
    <org_study_id>2018-01110</org_study_id>
    <nct_id>NCT03727399</nct_id>
  </id_info>
  <brief_title>Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients</brief_title>
  <official_title>Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mabylon AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mabylon AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be
      recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient
      samples suitable for antibody cloning are selected based on seroprofiling for the respective
      allergens. The study aims at isolating lymphocytes from patients with potential
      allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences
      obtained from B cells of those patients.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody profiling</measure>
    <time_frame>October 2018 - September 2021</time_frame>
    <description>Analysis and IgG profiling of specific antibodies binding major grass- and tree-pollen allergens in allergic patients.</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pollen Allergy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood withdrawal</intervention_name>
    <description>Blood withdrawal</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The project population will include adult (&gt; 18 years) patients with a history of grass and
        birch pollen allergy verified by positive skin prick test and allergen-specific IgE in
        blood. The study population may also include patients with ongoing or completed AIT.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass-
             or birch Allergens

          -  Male or female patients older than 18 years

          -  Written informed consent for providing blood and also to allow experimental
             manipulation

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Any corticosteroids within the last three days

          -  Oral corticosteroid therapy within the last ten days

          -  Parenteral depot corticosteroids within the last three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Immunologie Zentrum Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

